OMass Therapeutics expands leadership team with new CBO

Oxford-based OMass Therapeutics, a biotechnology company focused on medicine, has announced the appointment of Melissa Faris as Chief Business Officer.

Melissa joins from GSK, where she held the role of Vice President and Head of Immunology Business Development, leading a team responsible for end-to-end business development activities for immunology and infectious diseases.

Prior to this she held a number of senior executive business development roles at GSK both on the buy and sell side and  brings more than 25 years of experience in the biopharmaceutical industry in drug discovery, development and product commercialization.

Visit Hampshire Biz News for bright, upbeat and positive business news from the county

Melissa first started her career in clinical drug development at GlaxoWellcome in the US where she spent a decade leading and contributing to development programs for Respiratory medicines from Phase 1 through to registration and launch.

Ros Deegan, Chief Executive Officer at OMass Therapeutics, said: “Melissa’s broad experience in business and clinical development will be an invaluable asset for OMass as we advance our lead candidate toward IND enabling studies and continue to progress our exciting pipeline of immunology programs.

''In her new role Melissa will be instrumental in ensuring OMass secures high value partnerships and other opportunities to maximize the value of our assets and drug discovery platform, OdyssION.”

Read more - Shakespeare Martineau appoints eight newly-qualified solicitors